TY - JOUR
T1 - Multinational Association of Supportive Care in Cancer (MASCC) expert opinion/guidance on the use of clinically assisted hydration in patients with advanced cancer
AU - Hayes, Jo
AU - Bruera, Eduardo
AU - Crawford, Gregory
AU - Fleury, Mapi
AU - Santos, Marcos
AU - Thompson, Jo
AU - Davies, Andrew
N1 - Publisher Copyright:
© The Author(s) 2024.
PY - 2024/4
Y1 - 2024/4
N2 - Purpose: The provision of clinically assisted hydration (CAH) in patients with advanced cancer is controversial, and there is a paucity of specific guidance and so a diversity in clinical practice. Consequently, the Palliative Care Study Group of the Multinational Association of Supportive Care in Cancer (MASCC) formed a sub-group to develop evidence-based guidance on the use of CAH in patients with advanced cancer. Methods: This guidance was developed in accordance with the MASCC Guidelines Policy. A search strategy for Medline was developed, and the Cochrane Database of Systematic Reviews and the Cochrane Central Register of Controlled Trials were explored for relevant reviews/trials, respectively. Results: Due to the paucity of evidence, the sub-group was not able to develop a prescribed guideline, but was able to generate a number of “expert opinion statements”: these statements relate to assessment of patients, indications for CAH, contraindications for CAH, procedures for initiating CAH, and reassessment of patients. Conclusions: This guidance provides a framework for the use of CAH in advanced cancer, although every patient requires individualised management.
AB - Purpose: The provision of clinically assisted hydration (CAH) in patients with advanced cancer is controversial, and there is a paucity of specific guidance and so a diversity in clinical practice. Consequently, the Palliative Care Study Group of the Multinational Association of Supportive Care in Cancer (MASCC) formed a sub-group to develop evidence-based guidance on the use of CAH in patients with advanced cancer. Methods: This guidance was developed in accordance with the MASCC Guidelines Policy. A search strategy for Medline was developed, and the Cochrane Database of Systematic Reviews and the Cochrane Central Register of Controlled Trials were explored for relevant reviews/trials, respectively. Results: Due to the paucity of evidence, the sub-group was not able to develop a prescribed guideline, but was able to generate a number of “expert opinion statements”: these statements relate to assessment of patients, indications for CAH, contraindications for CAH, procedures for initiating CAH, and reassessment of patients. Conclusions: This guidance provides a framework for the use of CAH in advanced cancer, although every patient requires individualised management.
KW - Advanced cancer
KW - Clinically assisted hydration
KW - Neoplasms
KW - Palliative care
KW - Practice guideline
UR - http://www.scopus.com/inward/record.url?scp=85187739738&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85187739738&partnerID=8YFLogxK
U2 - 10.1007/s00520-024-08421-6
DO - 10.1007/s00520-024-08421-6
M3 - Review article
C2 - 38478135
AN - SCOPUS:85187739738
SN - 0941-4355
VL - 32
JO - Supportive Care in Cancer
JF - Supportive Care in Cancer
IS - 4
M1 - 228
ER -